CD51 distinguishes a subpopulation of bone marrow mesenchymal stem cells with distinct migratory potential: a novel cell-based strategy to treat acute myocardial infarction in mice.

ABSTRACT:

Background

Experimental and clinical trials have demonstrated the efficiency of bone marrow-derived mesenchymal stromal/stem cells (bMSCs) in the treatment of myocardial infarction. However, after intravenous injection, the ineffective migration of engrafted bMSCs to the hearts remains an obstacle, which has an undesirable impact on the efficiency of cell-based therapy. Therefore, we attempted to identify a marker that could distinguish a subpopulation of bMSCs with a promising migratory capacity.

Methods

Here, CD51-negative and CD51-positive cells were isolated by flow cytometry from Ter119^-CD45^-CD31^-bMSCs and cultured in specifically modified medium. The proliferation ability of the cells was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) sta

SUBMITTER: Xie DM 

PROVIDER: S-EPMC6865070 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature